798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

Bibliographic Details
Main Authors:	Aaron Scott, Manish Patel, Julie Bauman, Jeffrey Clarke, Howard Burris, Justin Gainor, Martin Gutierrez, Daniel Cho, Ricklie Julian, Pamela Cohen, Joshua Frederick, Celine Robert-Tissot, Honghong Zhou, Kinjal Mody, Karen Keating, Robert Meehan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
by: Wei Zheng, et al.
Published: (2023-11-01)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
by: Ying Cheng, MD, et al.
Published: (2021-10-01)

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
by: Petrella, T, et al.
Published: (2017)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
by: Lu Si, et al.
Published: (2022-10-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
by: Mei Zhan, et al.
Published: (2022-03-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
by: Vanessa Wookey, et al.
Published: (2021-06-01)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
by: Masaya Hattori, et al.
Published: (2023-05-01)

Keynotes
Published: (2023-05-01)

Keynotes
Published: (2016-01-01)

L1 F798 (43-49) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

PL 1.603/1996
by: - -
Published: (2023-04-01)

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
by: Ann W. Silk, et al.
Published: (2022-07-01)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
by: Lu Si, et al.
Published: (2019-06-01)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
by: Bhuwan Kumar
Published: (2021-01-01)

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
by: Razvan Cristescu, et al.
Published: (2024-01-01)

The morphogenesis of art districts: Case studies of Williamsburg, NYC and 798, Beijing
by: Christian Morgner
Published: (2014-12-01)

Keynote speech
by: Dobson, F
Published: (1998)

Keynote talk.
by: Granger, R
Published: (2006)

Keynote Speakers
Published: (2023-12-01)

Keynote Speeches
by: Fenton Natalie, et al.
Published: (2020-03-01)

Keynote Abstract
by: Mohd Dato’ Sabarudin, et al.
Published: (2016-01-01)

Keynote Speakers
by: Challenging Glass
Published: (2022-06-01)

Keynote Speakers
by: Challenging Glass
Published: (2016-06-01)

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
by: S. Kümmel, et al.
Published: (2023-03-01)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022-10-01)

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
by: Toshiharu Hirose, et al.
Published: (2023-01-01)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
by: Åse Bratland, et al.
Published: (2023-11-01)

A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

261 Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180
by: Takashi Kojima, et al.
Published: (2020-11-01)

798 TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy
by: Jennifer Wang, et al.
Published: (2023-11-01)

Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study
by: Philippou, Y, et al.
Published: (2020)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial
by: Philippe Merle, et al.
Published: (2023-02-01)

KEYNOTE-641 phase 3 study of pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer
by: A. Stenzl, et al.
Published: (2020-07-01)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

Keynotes in organic chemistry /
by: Parsons, A. F.
Published: (2014)

Keynotes in organic chemistry /
by: 212803 Parsons, Andrew F.
Published: (2003)

KEYNOTE: THE BIOGRAPHY OF OBJECTS
by: C. Greco
Published: (2019-05-01)